Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2− Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only
Martin Filipits(University of Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Ralf Kronenwett(Beth Israel Deaconess Medical Center), Florian Fitzal, Ryan Bernhisel(Myriad Genetics), Richard Greil(Paracelsus Medical University), Johnathan M. Lancaster(University of South Florida), Margaretha Rudas(Comprehensive Cancer Center Vienna), Peter Dubsky(Hirslanden Klinik St. Anna), Marija Balić(University of Pittsburgh), Dominik Hlauschek(Austrian Breast & Colorectal Cancer Study Group), Krystal Brown(Myriad Genetics), Christian F. Singer(Comprehensive Cancer Center Vienna)
Cited by 77
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k